Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

75
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
75
Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters01:16

Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters

99
The pharmacogenetics of drug transporters is increasingly recognized as a critical factor influencing interindividual variability in drug absorption, distribution, and elimination. These membrane-bound proteins regulate drugs' movement across cellular barriers by actively pumping them out (efflux) or facilitating their uptake (influx). Among the major transporter families, ATP-binding cassette (ABC) and solute carrier (SLC) transporters play particularly prominent roles. Genetic polymorphisms...
99
Principles of Pharmacogenetics: Types of Genetic Variants01:27

Principles of Pharmacogenetics: Types of Genetic Variants

79
The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...
79
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

98
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
98
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion01:20

Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion

269
Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
269
Single Nucleotide Polymorphisms-SNPs01:05

Single Nucleotide Polymorphisms-SNPs

19.6K
A single nucleotide polymorphism or SNP is a single nucleotide variation at a specific genomic position in a large population. It is the most prevalent type of sequence variation found in the human genome. Point mutations that occur in more than 1% of the population qualify as SNPs. These are present once every 1000 nucleotides on an average in the human genome. Replacement of a purine with another purine (A/G) or a pyrimidine with another pyrimidine (C/T) is known as a transition. In contrast,...
19.6K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The Psyche Multispectral Imager Investigation: Characterizing the Geology, Topography, and Multispectral Properties of a Metal-Rich World.

Space science reviews·2025
Same author

The epigenetic EZH2/H3K27me3 axis modulates lactotroph tumor cell proliferation.

The Journal of endocrinology·2023
Same author

Impact of 10-Day Fulbright Specialist Program and Project Pink Blue Education Sessions on Medical Oncology Knowledge Among Physicians Who Treat Cancer in Nigeria.

Journal of cancer education : the official journal of the American Association for Cancer Education·2022
Same author

Care pathways in atopic dermatitis: a retrospective population-based cohort study.

Journal of the European Academy of Dermatology and Venereology : JEADV·2022
Same author

Cost-effectiveness of romosozumab for the treatment of postmenopausal women with severe osteoporosis at high risk of fracture in Sweden.

Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA·2021
Same author

A novel economic framework to assess the cost-effectiveness of bone-forming agents in the prevention of fractures in patients with osteoporosis.

Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA·2021

Related Experiment Video

Updated: Mar 19, 2026

A High-Throughput Luciferase Assay to Evaluate Proteolysis of the Single-Turnover Protease PCSK9
08:14

A High-Throughput Luciferase Assay to Evaluate Proteolysis of the Single-Turnover Protease PCSK9

Published on: August 28, 2018

8.7K

PCSK1 Variants and Human Obesity.

B Ramos-Molina1, M G Martin2, I Lindberg3

  • 1Department of Human Genetics, KU Leuven, Leuven, Belgium.

Progress in Molecular Biology and Translational Science
|June 12, 2016
PubMed
Summary
This summary is machine-generated.

Prohormone convertase 1/3 (PCSK1) deficiency causes early-onset obesity and endocrinopathies. Novel mutations reveal complex cellular pathologies, offering insights into potential treatments for PCSK1 deficiency disorders.

Keywords:
PC1/3PCSK1feedinggenome-wide association studiesglucose metabolismobesitypeptide hormoneposttranslational processingprohormone convertase 1/3secretory pathway

More Related Videos

LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring
08:45

LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring

Published on: November 17, 2018

14.2K
Generation of High Quality Chromatin Immunoprecipitation DNA Template for High-throughput Sequencing ChIP-seq
09:52

Generation of High Quality Chromatin Immunoprecipitation DNA Template for High-throughput Sequencing ChIP-seq

Published on: April 19, 2013

25.0K

Related Experiment Videos

Last Updated: Mar 19, 2026

A High-Throughput Luciferase Assay to Evaluate Proteolysis of the Single-Turnover Protease PCSK9
08:14

A High-Throughput Luciferase Assay to Evaluate Proteolysis of the Single-Turnover Protease PCSK9

Published on: August 28, 2018

8.7K
LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring
08:45

LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring

Published on: November 17, 2018

14.2K
Generation of High Quality Chromatin Immunoprecipitation DNA Template for High-throughput Sequencing ChIP-seq
09:52

Generation of High Quality Chromatin Immunoprecipitation DNA Template for High-throughput Sequencing ChIP-seq

Published on: April 19, 2013

25.0K

Area of Science:

  • Endocrinology
  • Genetics
  • Molecular Biology

Background:

  • Prohormone convertase 1/3 (PC1/3), encoded by PCSK1, is crucial for processing peptide hormones regulating appetite and metabolism.
  • PCSK1 gene variations are linked to obesity risk, and its deficiency causes early-onset obesity and endocrinopathies.
  • Recent genetic studies identify novel PCSK1 mutations in infants with persistent diarrhea, leading to malabsorption and later hyperphagic obesity.

Purpose of the Study:

  • To investigate the molecular and cellular mechanisms underlying PCSK1 deficiency.
  • To understand how novel PCSK1 mutations contribute to endocrinopathies, including obesity.
  • To explore potential therapeutic strategies for PCSK1 deficiency.

Main Methods:

  • Biochemical characterization of novel loss-of-function PCSK1 mutations.
  • Analysis of cellular pathologies, including dominant-negative effects and endoplasmic reticulum retention.
  • Genetic diagnosis in infants with persistent diarrhea and subsequent obesity.

Main Results:

  • Identification of novel PCSK1 mutations in infants with severe intestinal malabsorption and subsequent hyperphagic obesity.
  • Discovery of pathological mechanisms beyond simple enzyme loss, such as dominant-negative effects and ER stress.
  • Established PCSK1 deficiency as a cause of complex endocrinopathies.

Conclusions:

  • PCSK1 deficiency leads to severe metabolic and endocrine disorders, including obesity.
  • Novel PCSK1 mutations unveil complex cellular dysfunctions impacting endocrine cell biology.
  • Understanding these mechanisms is key to developing treatments for PCSK1 deficiency.